Literature DB >> 7912629

Classical and atypical binding sites for beta-adrenoceptor ligands and activation of adenylyl cyclase in bovine skeletal muscle and adipose tissue membranes.

M N Sillence1, M L Matthews.   

Abstract

1. The radioligand [125I]-iodocyanopindolol ([125I]-ICYP) was used under standard ligand binding conditions, to detect beta 1- and beta 2-adrenoceptors in membrane preparations from bovine skeletal muscle and adipose tissue. High concentrations of [125I]-ICYP were also used, to identify an 'atypical' binding site in skeletal muscle. Finally, adenosine 3':5'-cyclic monophosphate (cyclic AMP) production was measured in the same membrane preparations, to determine the relationship between the beta-adrenoceptor sub-types present and the production of this second-messenger. 2. According to the results of radioligand binding studies, both skeletal muscle and adipose tissue membranes have beta 2-adrenoceptors, characterized by a high affinity for the beta 2-selective antagonist, ICI 118551 (pK 8.3 and 8.6 respectively); and a low affinity for the beta 1-selective antagonist CGP 20712A (pK 5.2 in both tissues). Antagonism of (-)-isoprenaline-stimulated cyclic AMP production by low concentrations of ICI 118551, yielded pseudo pA2 values in muscle and adipose tissue of 7.6 and 8.7 respectively, confirming that beta 2-adrenoceptors in these tissues are linked to the production of the second-messenger. 3. Although beta 1-adrenoceptors could not be detected in either skeletal muscle or adipose tissue membranes by use of ligand binding techniques, high pseudo pA2 values were obtained (8.0 and 8.2 respectively), when CGP 20712A was used to block the stimulation of cyclic AMP production by (-)-isoprenaline. This finding is consistent with the presence in both tissues of a population of beta 1-adrenoceptors which is small, but efficiently coupled to the second-messenger. 4.In addition to identifying standard beta 1- and beta 2-adrenoceptors, it was also established that skeletal muscle membranes have an 'atypical' binding site which has a relatively low affinity for [125]-ICYP(pK8.84), but which exists in abundance. At high concentrations of radioligand, the 'atypical' site accounted for 89% of the total [125I]-ICYP binding sites present.5. The results of second-messenger studies do not support the hypothesis that skeletal muscle or adipose tissue membranes contain functional beta 3-adrenoceptors: based on the failure of a beta 3-adrenoceptor-selective agonist (BRL 37344) to stimulate cyclic AMP production, the absence of a biphasic response to (-)-isoprenaline, and the observation that cyclic AMP production was not resistant to blockade by either ICI 118551 or CGP20712A.6. It is concluded that data from radioligand binding studies do not accurately reflect the contribution made by beta 1- and beta 2-adrenoceptors to cyclic AMP production in bovine skeletal muscle and adipose tissue membranes. Furthermore, the 'atypical' [125I]-ICYP binding site identified in bovine skeletal muscle does not represent a functional bovine beta 3-adrenoceptor.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912629      PMCID: PMC1910079          DOI: 10.1111/j.1476-5381.1994.tb14818.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Characterization of beta-adrenoceptors on rat skeletal muscle cells grown in vitro.

Authors:  M H Disatnik; S R Sampson; A Shainberg
Journal:  Biochem Pharmacol       Date:  1990-09-01       Impact factor: 5.858

2.  Regulation of beta 1- and beta 2-adrenoceptors following chronic treatment with beta-adrenoceptor antagonists.

Authors:  M S Elfellah; J L Reid
Journal:  Eur J Pharmacol       Date:  1989-11-28       Impact factor: 4.432

3.  Direct evidence for the atypical nature of functional beta-adrenoceptors in rat adipocytes.

Authors:  C Hollenga; J Zaagsma
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

4.  Ascorbic acid-induced binding of [125I]-iodocyanopindolol to non-beta-adrenoceptor sites in guinea-pig trachea.

Authors:  P J Rigby; M C Passarelli; G J Self; J M Preuss; R G Goldie
Journal:  Biochem Pharmacol       Date:  1988-04-01       Impact factor: 5.858

5.  Atypical beta-adrenergic receptor in 3T3-F442A adipocytes. Pharmacological and molecular relationship with the human beta 3-adrenergic receptor.

Authors:  B Fève; L J Emorine; F Lasnier; N Blin; B Baude; C Nahmias; A D Strosberg; J Pairault
Journal:  J Biol Chem       Date:  1991-10-25       Impact factor: 5.157

6.  Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species.

Authors:  D Langin; M P Portillo; J S Saulnier-Blache; M Lafontan
Journal:  Eur J Pharmacol       Date:  1991-07-09       Impact factor: 4.432

7.  Characterization of beta 1- and beta 2-adrenoceptors in rat skeletal muscles.

Authors:  Y S Kim; R D Sainz; P Molenaar; R J Summers
Journal:  Biochem Pharmacol       Date:  1991-10-09       Impact factor: 5.858

8.  Characterization of beta-adrenergic receptors of human skeletal muscle obtained by needle biopsy.

Authors:  S B Liggett; S D Shah; P E Cryer
Journal:  Am J Physiol       Date:  1988-06

9.  Norepinephrine and BRL 37344 stimulate adenylate cyclase by different receptors in rat brown adipose tissue.

Authors:  J G Granneman
Journal:  J Pharmacol Exp Ther       Date:  1990-08       Impact factor: 4.030

10.  Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes.

Authors:  C Nahmias; N Blin; J M Elalouf; M G Mattei; A D Strosberg; L J Emorine
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  7 in total

1.  Biphasic effects of the beta-adrenoceptor agonist, BRL 37344, on glucose utilization in rat isolated skeletal muscle.

Authors:  Y L Liu; M A Cawthorne; M J Stock
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

2.  Short Communication: Beta-adrenergic agonists alter oxidative phosphorylation in primary myoblasts.

Authors:  Renae L Sieck; Leah K Treffer; Anna M Fuller; Martonio Ponte Viana; Oleh Khalimonchuk; Ty B Schmidt; Dustin T Yates; Jessica L Petersen
Journal:  J Anim Sci       Date:  2022-08-01       Impact factor: 3.338

3.  Lubabegron fumarate acts as a β-adrenergic receptor antagonist in cultured bovine intramuscular and subcutaneous adipocytes.

Authors:  Jinhee H Hwang; John C Kube; Stephen B Smith
Journal:  J Anim Sci       Date:  2022-03-01       Impact factor: 3.338

4.  Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats.

Authors:  James G Ryall; David R Plant; Paul Gregorevic; Martin N Sillence; Gordon S Lynch
Journal:  J Physiol       Date:  2003-11-14       Impact factor: 5.182

5.  Historical Overview of the Effect of β-Adrenergic Agonists on Beef Cattle Production.

Authors:  Bradley J Johnson; Stephen B Smith; Ki Yong Chung
Journal:  Asian-Australas J Anim Sci       Date:  2014-05       Impact factor: 2.509

6.  Comparison of beta-ligands used in cattle production: structures, safety, and biological effects.

Authors:  Anna C Dilger; Bradley J Johnson; Paul Brent; Richard L Ellis
Journal:  J Anim Sci       Date:  2021-08-01       Impact factor: 3.159

7.  Characterization of β-adrenergic receptors in bovine intramuscular and subcutaneous adipose tissue: comparison of lubabegron fumarate with β-adrenergic receptor agonists and antagonists.

Authors:  Jinhee H Hwang; Michael E Spurlock; John C Kube; Xiang Z Li; Stephen B Smith
Journal:  J Anim Sci       Date:  2021-08-01       Impact factor: 3.159

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.